Question · asked by 1 review
Pregabalin vs placebo: Treatment‐related adverse effects
- Population
- adults and children with sickle cell disease experiencing neuropathic pain
- Intervention
- Pregabalin
- Comparison
- placebo
- Outcome
- Treatment‐related adverse effects
It is very uncertain whether summary of findings ‐ Pharmacological intervention (pregabalin) changes treatment‐related adverse effects compared with placebo (very low certainty).
What each review found
Include earlier review versions| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Summary of findings ‐ Pharmacological intervention (pregabalin) vs placebo Treatment‐related adverse effects · adults and children with sickle cell disease experiencing neuropathic pain It is very uncertain whether summary of findings ‐ Pharmacological intervention (pregabalin) changes treatment‐related adverse effects compared with placebo (very low certainty). Interventions for treating neuropathic pain in people with sickle cell disease (2019) · Cochrane Headline outcomes only | RR 1.33 | 1 study · 22 participants | Very low |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Interventions for treating neuropathic pain in people with sickle cell disease 2019 · Cochrane Headline outcomes only | Not reported | Not extracted | Not assessed |
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.